222631-83-6

Basic information

• Product Name: 1H-Pyrazolo4,3-dpyrimidine-5,7(4H,6H)-dione, 3-(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-pyrrolidinyl-
• Synonyms: 1H-Pyrazolo4,3-dpyrimidine-5,7(4H,6H)-dione, 3-(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-pyrrolidinyl-
• CAS NO: 222631-83-6
• Molecular Formula: C10H13 N5 O4
• Molecular Weight: 267.24
• Mol File: 222631-83-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrazolo4,3-dpyrimidine-5,7(4H,6H)-dione, 3-(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-pyrrolidinyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo4,3-dpyrimidine-5,7(4H,6H)-dione, 3-(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-pyrrolidinyl-(222631-83-6)
• EPA Substance Registry System: 1H-Pyrazolo4,3-dpyrimidine-5,7(4H,6H)-dione, 3-(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-pyrrolidinyl-(222631-83-6)

Safety Data

• Hazardous Substances Data: 222631-83-6(Hazardous Substances Data)

Relevant articles and documents

Inhibitors of nucleoside metabolism

The present invention provides compounds having the formula: wherein A is CH or N; B is chosen from OH, NH2, NHR, H or halogen; D is chosen from OH, NH2, NHR, H, halogen or SCH3; R is an optionally substituted alkyl, aralkyl or aryl group; and X and Y are independently selected from H, OH or halogen except that when one of X and Y is hydroxy or halogen, the other is hydrogen; and Z is OH or, when X is hydroxy, Z is selected from hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted alkyl, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof; and compounds having the formula: wherein A, X, Y, Z and R are defined for compounds of formula (I) where first shown above; E is chosen from CO2H or a corresponding salt form, CO2R, CN, CONH2, CONHR or CONR2; and G is chosen from NH2, NHCOR, NHCONHR or NHCSNHR; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof. The present invention also provides the use of the above compounds as pharmaceuticals, pharmaceutical compositions containing the compounds and processes for preparing the compounds.

Inhibitors of nucleoside metabolism

The present invention provides compounds having the formula: STR1 wherein A is CH or N; B is chosen from OH, NH2, NHR, H or halogen; D is chosen from OH, NH2, NHR, H, halogen or SCH3 ; R is an optionally substituted alkyl, aralkyl or aryl group; and X and Y are independently selected from H, OH or halogen except that when one of X and Y is hydroxy or halogen, the other is hydrogen; and Z is OH or, when X is hydroxy, Z is selected from hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted alkyl, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof. The present invention also provides the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds and processes for preparing the compounds.